• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Faeth Therapeutics, Inc. - Common Stock (NQ:FTH)

26.35 -0.54 (-2.01%)
Delayed Quote Updated: 10:00 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,957
Open 26.71
Bid (Size) 26.17 (200)
Ask (Size) 26.55 (300)
Prev. Close 26.89
Today's Range 26.03 - 26.71
52wk Range 13.43 - 42.14
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout ↗
Today 4:02 EDT
Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The... 
Via MarketBeat
News headline image
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
September 17, 2026
From Faeth Therapeutics, Inc.
Via Business Wire

Performance

52-Week Range 37.5% below 52-week high
26.35
13.4352W Low 42.1452W High
1 Week 15.4% below 1-week high
25.781W Low 31.131W High

Faeth Therapeutics, Inc. - Common Stock (FTH) traded between $13.43 and $42.14 over the past 52 weeks and last traded at $26.35, 37.5% below its 52-week high. Over the past week it ranged between $25.78 and $31.13.

Past 12 Months
-11.4%
-32.8%
+0.9%
+81.3%
+81.3%
+81.3%
1W -$3.39
1M -$12.85
3M +$0.24
6M +$11.82
YTD +$11.82
1Y +$11.82

FTH was +81.3% over the past year, +81.3% over six months, +81.3% year to date, -11.4% in the last week.

12 Months vs Market
FTH
+81.3%
DIA
+9.1%
SPY
+15.3%
QQQ
+24.0%
IWM
+12.7%

Over the past 12 months FTH returned +81.3% versus DIA (Dow) +9.1%, SPY (S&P 500) +15.3%, QQQ (Nasdaq 100) +24.0% and IWM (Russell 2000) +12.7%.

Volume & Liquidity 0.10× 3-mo avg
Today 34,957 3-mo avg 345.6K
1W
303.0K
1M
439.9K
3M
345.6K
6M
307.6K
YTD
307.6K
1Y
307.6K

FTH most recently traded 34,957 shares against a 3-month average daily volume of 345.6K.

More News

Read More
News headline image
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
September 08, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
September 01, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
August 17, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
August 14, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
August 07, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
August 04, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 23, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2026
From Faeth Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Faeth Therapeutics, Inc. - Common Stock publicly traded?
Yes, Faeth Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Faeth Therapeutics, Inc. - Common Stock trade on?
Faeth Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Faeth Therapeutics, Inc. - Common Stock?
The ticker symbol for Faeth Therapeutics, Inc. - Common Stock is FTH on the Nasdaq Stock Market
What is the current price of Faeth Therapeutics, Inc. - Common Stock?
The current price of Faeth Therapeutics, Inc. - Common Stock is 26.35
When was Faeth Therapeutics, Inc. - Common Stock last traded?
The last trade of Faeth Therapeutics, Inc. - Common Stock was at 10/07/26 10:00 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap